课题基金 / 基金详情

The RB Gene Family in Cancer Initiation

The RB Gene Family in Cancer Initiation
癌症发生中的 RB 基因家族
批准号:
7426780
负责人:
JULIEN SAGE
金额:
$27.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2011-05-31

项目摘要

项目成果

JULIEN SAGE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):视网膜母细胞瘤(RB)基因是一种有效的人类癌症抑制因子。虽然Rb被认为在细胞周期中具有多种功能,但对其肿瘤抑制活性至关重要的Rb的特定功能仍不清楚。我们建议测试Rb及其两个相关家族成员p107和p130通过控制细胞周期GO和G1期之间的转换在体内预防癌症起始中发挥关键作用的想法。具体地说,我们假设,RB家族功能的急性丧失导致关键细胞群体中细胞周期退出(G1->GO)和细胞周期重新进入(GO-gt;G1)的缺陷,并且这些缺陷可能导致肿瘤发生的启动。我们将使用Rb家族基因的生殖系和条件性突变组合的小鼠模型来验证我们的假设。这种小鼠遗传学方法将使我们能够确定Rb家族基因在空间和时间定义的细胞群体中的作用。这些小鼠模型还将使我们能够在体内重述人类癌症的早期阶段。第一个特定目标的研究将表征Rb家族基因在胚胎发育过程中细胞周期退出中的功能。视网膜母细胞瘤患者早在胎儿期就会患上视网膜母细胞瘤,这是视网膜神经肿瘤。我们将重点研究神经前体细胞,以探索Rb家族功能丧失对细胞周期退出和导致癌症发生的分化缺陷的影响。对第二个特定目标的研究将确定Rb家族蛋白是否是维持体内分化所必需的。具体地说,我们将研究Rb家族基因的急性功能丧失对体内分化的肝细胞重新进入细胞周期的影响。这些研究将对确定一些终末分化细胞是否可能是癌症的起源具有重要意义。第三个特定目标的研究将结合分子方法和体内RNA干扰,以了解体内Rb家族功能丧失后细胞周期重新进入的分子机制。我们将重点研究Rb家族突变肝细胞中细胞周期重入的候选介质,包括E2F转录激活因子和Id2转录抑制因子。了解体内Rb家族肿瘤抑制基因缺失的分子基础和细胞后果,将为肿瘤的发生机制提供重要而新颖的见解。这些研究将进一步为人类癌症早期的发现和治疗提供基础。
英文摘要
DESCRIPTION (provided by applicant): The retinoblastoma (RB) gene is a potent suppressor of human cancers. While RB is thought to have multiple functions during the cell cycle, the specific functions of RB that are critical for its tumor suppression activity are still unclear. We propose to test the idea that RB and its two related family members p107 and p130 play a pivotal role in preventing cancer initiation in vivo by controlling the transition between the GO and G1 phase of the cell cycle. Specifically, we hypothesize that the acute somatic loss of RB family function leads to defects in both cell cycle exit (G1->GO) and cell cycle re-entry (GO->G1) in critical cell populations, and that these defects may result in the initiation of tumorigenesis. We will test our hypothesis using mouse models with combinations of germline and conditional mutations of RB family genes. This mouse genetic approach will enable us to determine the role of RB family genes in spatially and temporally-defined cell populations. These mouse models will also allow us to recapitulate in vivo the early stages of cancer in humans. Studies in the first Specific Aim will characterize the function of RB family genes in cell cycle exit during embryonic development. RB patients develop retinoblastomas, which are retinal neural tumors, as early as the fetal stage. We will focus our studies on neural progenitors to explore the consequences of loss of RB family function on cell cycle exit and differentiation defects leading to cancer initiation. Studies in the second Specific Aim will determine if the RB family proteins are required for maintenance of differentiation in vivo. Specifically, we will investigate the consequences of acute loss of function of RB family genes on cell cycle re-entry of differentiated hepatocytes in vivo. These studies will be important to determine if some terminally differentiated cells may be at the origin of cancer. Studies in the third Specific Aim will combine molecular approaches and RNA interference in vivo to understand the molecular mechanisms underlying cell cycle re-entry upon loss of RB family function in vivo. We will focus our studies on candidate mediators of cell cycle re-entry in RB family mutant hepatocytes, including the E2F transcriptional activator and the Id2 transcriptional repressor. Understanding the molecular bases and the cellular consequences of the loss of RB family tumor suppressors in vivo will give important and novel insights into the mechanisms of cancer initiation. These studies will further provide the foundation for the detection and treatment of early stages of human cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2: To determine the consequences of activating Rb function in cancer cells
  • 批准号:
    10597166
  • 项目类别:
  • 资助金额:
    $23.44万
  • 财政年份:
    2022
  • 负责人:
    JULIEN SAGE
  • 依托单位:
Project 2: To determine the consequences of activating Rb function in cancer cells
  • 批准号:
    10332381
  • 项目类别:
  • 资助金额:
    $27.65万
  • 财政年份:
    2022
  • 负责人:
    JULIEN SAGE
  • 依托单位:
Core A: Determining and targeting mechanisms controlling cancer cell division
  • 批准号:
    10597192
  • 项目类别:
  • 资助金额:
    $23.44万
  • 财政年份:
    2022
  • 负责人:
    JULIEN SAGE
  • 依托单位:
Core A: Determining and targeting mechanisms controlling cancer cell division
  • 批准号:
    10332383
  • 项目类别:
  • 资助金额:
    $27.65万
  • 财政年份:
    2022
  • 负责人:
    JULIEN SAGE
  • 依托单位:
海外基金